ALTEOGEN Inc. (196170.KQ)
KRW 286500.0
(-3.54%)
KRW 286500.0
(-3.54%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 108.25 Billion KRW | 8.14% |
| 2022 | 100.1 Billion KRW | -21.05% |
| 2021 | 126.79 Billion KRW | 28.56% |
| 2020 | 98.62 Billion KRW | 525.2% |
| 2019 | 15.77 Billion KRW | 296.1% |
| 2018 | 3.98 Billion KRW | 47.53% |
| 2017 | 2.69 Billion KRW | 14.06% |
| 2016 | 2.36 Billion KRW | 472.77% |
| 2015 | 413.19 Million KRW | -61.54% |
| 2014 | 1.07 Billion KRW | -52.86% |
| 2013 | 2.27 Billion KRW | 18.91% |
| 2012 | 1.91 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 120.55 Billion KRW | 14.69% |
| 2024 Q1 | 105.11 Billion KRW | -2.9% |
| 2023 FY | 108.25 Billion KRW | 8.14% |
| 2023 Q4 | 108.25 Billion KRW | 1.3% |
| 2023 Q1 | 113.38 Billion KRW | 13.27% |
| 2023 Q3 | 106.86 Billion KRW | 3.12% |
| 2023 Q2 | 103.62 Billion KRW | -8.61% |
| 2022 Q4 | 100.1 Billion KRW | 1.12% |
| 2022 Q2 | 103.25 Billion KRW | 2.77% |
| 2022 FY | 100.1 Billion KRW | -21.05% |
| 2022 Q1 | 100.47 Billion KRW | -20.52% |
| 2022 Q3 | 99 Billion KRW | -4.11% |
| 2021 Q4 | 126.41 Billion KRW | 60.41% |
| 2021 FY | 126.79 Billion KRW | 28.56% |
| 2021 Q2 | 80.12 Billion KRW | 263.91% |
| 2021 Q3 | 78.8 Billion KRW | -1.64% |
| 2021 Q1 | 22.01 Billion KRW | 74.06% |
| 2020 Q4 | 12.64 Billion KRW | -4.36% |
| 2020 Q3 | 13.22 Billion KRW | -4.4% |
| 2020 Q1 | 10.32 Billion KRW | -27.1% |
| 2020 Q2 | 13.83 Billion KRW | 33.97% |
| 2020 FY | 98.62 Billion KRW | 525.2% |
| 2019 Q2 | 9.43 Billion KRW | 79.74% |
| 2019 Q3 | 9.01 Billion KRW | -4.43% |
| 2019 FY | 15.77 Billion KRW | 296.1% |
| 2019 Q1 | 5.24 Billion KRW | 12.04% |
| 2019 Q4 | 14.16 Billion KRW | 57.12% |
| 2018 Q1 | 2.53 Billion KRW | -6.01% |
| 2018 Q4 | 4.68 Billion KRW | -12.48% |
| 2018 FY | 3.98 Billion KRW | 47.53% |
| 2018 Q2 | 34.78 Billion KRW | 1273.12% |
| 2018 Q3 | 5.35 Billion KRW | -84.61% |
| 2017 Q1 | 1.36 Billion KRW | -38.46% |
| 2017 FY | 2.69 Billion KRW | 14.06% |
| 2017 Q3 | 1.74 Billion KRW | 30.74% |
| 2017 Q2 | 1.33 Billion KRW | -2.61% |
| 2017 Q4 | 2.69 Billion KRW | 54.66% |
| 2016 Q2 | 1.54 Billion KRW | 241.02% |
| 2016 Q3 | 1.28 Billion KRW | -16.86% |
| 2016 Q4 | 2.22 Billion KRW | 72.79% |
| 2016 FY | 2.36 Billion KRW | 472.77% |
| 2016 Q1 | 453.97 Million KRW | 9.87% |
| 2015 FY | 413.19 Million KRW | -61.54% |
| 2015 Q2 | 348.94 Million KRW | -35.99% |
| 2015 Q1 | 545.17 Million KRW | -49.26% |
| 2015 Q3 | 268.32 Million KRW | -23.11% |
| 2015 Q4 | 413.19 Million KRW | 53.99% |
| 2014 Q4 | 1.07 Billion KRW | 0.0% |
| 2014 FY | 1.07 Billion KRW | -52.86% |
| 2014 Q2 | 3.38 Billion KRW | 0.0% |
| 2014 Q1 | - KRW | -100.0% |
| 2013 Q3 | 2.27 Billion KRW | 0.0% |
| 2013 Q1 | - KRW | 0.0% |
| 2013 Q4 | 2.27 Billion KRW | 0.0% |
| 2013 FY | 2.27 Billion KRW | 18.91% |
| 2012 FY | 1.91 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 36.121% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -5657.309% |
| BINEX Co., Ltd. | 75.68 Billion KRW | -43.036% |
| Bioneer Corporation | 80.61 Billion KRW | -34.298% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -441.65% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 20.243% |
| CrystalGenomics, Inc. | 97.82 Billion USD | -10.668% |
| Helixmith Co., Ltd | 73.55 Billion KRW | -47.175% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 89.875% |
| Medy-Tox Inc. | 137.14 Billion KRW | 21.06% |
| Peptron, Inc. | 16.36 Billion KRW | -561.363% |
| Amicogen, Inc. | 248.12 Billion KRW | 56.369% |
| Genexine, Inc. | 79.68 Billion KRW | -35.861% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -269.785% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -162.248% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -48.123% |
| SillaJen, Inc. | 19.4 Billion KRW | -458.005% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 39.551% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -106.249% |
| Genomictree Inc. | 7.81 Billion KRW | -1285.748% |
| MedPacto, Inc. | 9.56 Billion KRW | -1031.731% |
| D&D Pharmatech | 23.98 Billion KRW | -351.346% |
| EASY BIO,Inc. | 105.86 Billion KRW | -2.257% |
| GI Innovation, Inc. | 9.63 Billion KRW | -1023.454% |